MedWatch

Ambu retires main argument for single-use endoscopes

The argument that reusable equipment increases the risk of spreading infections does not seem to have gained ground in hospitals – so the medtech company is coming up with different reasons.

Under a new strategy, Meelby Jensen will attempt to win over the endoscope market with a different selling point | Photo: Ambu/pr

Chief Executive Officer at Ambu Britt Meelby Jensen is ending a persuasion tactic for why the market should make a switch from reusable endoscope to single-use products.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs